Thermo Fisher Scientific Expands China Presence Through New Customer Solutions Center

News
Article

The new center will handle the delivery of novel and high-quality therapeutics by providing expertise in critical analytical processes and specialized workflows.

Thermo Fisher Scientific announced on Nov. 13, 2019 that it is opening a customer solutions center in Shanghai, China, furthering the company’s efforts to expand its presence in China. The company also recently announced the opening of a biosciences customer exploration center in Shanghai and the expansion of its clinical trials logistics facility in Suzhou, China.

According to a company press release, the new center will handle the delivery of novel and high-quality therapeutics by providing expertise in critical analytical processes and specialized workflows.

"The opening of a Pharma and BioPharma [c]ustomer [s]olution [c]enter in China demonstrates our unwavering commitment to bringing best-in-class analytical technologies to laboratories across the region and supporting quality-by-design through scientific collaboration by scientists," said Tony Acciarito, president of Thermo Fisher Scientific in China, in the press release. "The new [c]enter reinforces our mission of enabling our customers to make the world healthier, cleaner, and safer by helping laboratories in China nurture innovation and bring effective medicines to waiting patients."

"Thermo Fisher's new [c]ustomer [s]olution ]c]enter in Shanghai is a hub of collaboration that will enable scientists across China to build new analytical workflows, enhance knowledge across our thriving pharmaceutical and biopharmaceutical sector, and help build capability and expertise in the region,” added Zhong Feng, director, Shandong New Time Pharmaceutical, in the press release.

Source: Thermo Fisher Scientific

 

 

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Related Content